Please login to the form below
Blueprint Medicines
This page shows the latest Blueprint Medicines news and features for those working in and with pharma, biotech and healthcare.
Roche announces positive phase 3 results for Alecensa in early-stage lung cancer
FDA) and the European Medicines Agency (EMA). ... The positive readout comes just a few weeks after Roche’s Genentech unit and Blueprint Medicines received full approval from the FDA for use of their targeted cancer therapy, Gavreto (pralsetinib),
Latest news
-
Eli Lilly shares positive late-stage results for Retevmo in thyroid cancer
The latest results for Retevmo come just a few weeks after Roche said it would be withdrawing its Blueprint Medicines-partnered Gavreto (pralsetinib) from the US RET-mutant MTC market, citing
-
Roche’s Genentech and Blueprint receive full FDA approval for Gavreto in lung cancer
Roche’s Genentech unit and Blueprint Medicines have received full approval from the US Food and Drug Administration (FDA) for use of their targeted cancer therapy, Gavreto (pralsetinib), in a subset ... Gavreto was jointly developed and commercialised
-
FDA approves Blueprint Medicines’ Ayvakit for indolent systemic mastocytosis
The US Food and Drug Administration (FDA) has approved Blueprint Medicines’ Ayvakit (avapritinib) as the first and only medicine designed to treat indolent systemic mastocytosis (ISM). ... Blueprint’s chief medical officer, Becker Hewes, said the
-
Roche pays $775m upfront to access Blueprint’s RET programme
Expands on initial deal that is worth up to $1bn. Roche has expanded its existing collaboration with Blueprint Medicines, signing a new deal which will see it gain rights to the ... development of pralsetinib across multiple treatment settings where
-
Revenue growth at Ipsen numbs pain of palovarotene calamity
for Blueprint Medicines’ BLU-782, an ALK2 inhibitor in phase 1 development for the treatment of FOP.
More from news
Approximately 7 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Integrating patient reported outcomes into clinical trials
And Blueprint Medicines created a proprietary PRO for its mastocytosis drug. ... Blueprint Medicines is one company that took matters into its own hands.
-
Spotlight on Patient Engagement
Open Conversations: Pathway to Launch Excellence It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.
-
Open Conversations: Pathway to Launch Excellence
Open Conversations: Pathway to Launch Excellence. It is widely acknowledged that yesterday’s playbook no longer provides the best blueprint for launching tomorrow’s medicines.
-
Deal Watch March 2016
Roche has paid $45m upfront with $965m in contingent fees, including options, milestones and royalties for the rights to up to five small molecules from Blueprint Medicines' drug discovery platform. ... Acquisition of royalty rights. $1, 140. Blueprint
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Subscribe to our email news alerts
- Planting the Seeds for Future Women Leaders in Medicine
- FDA approves SpringWork’s Ogsiveo as first therapy for desmoid tumours
- GSK shares positive phase 3 results for Blenrep combination in multiple myeloma
- Stem cell therapy trial shows promising results for treating progressive MS
- Cancer Research UK calls on government to create ten-year cancer plan
- Risk calculator to prevent heart attacks and strokes in type 2 diabetes patients
No results were found
PMHub
11 London
We live in a hyper-connected world. This has clear benefits for the health of our communities, our businesses and our...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
